Clinical efficacy of Fuzheng Jiedu Xiaoyong granules in advanced colorectal cancer (spleen deficiency and stasis toxin syndrome)

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 2

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Oncol. Feb 15, 2026; 18(2): 113922
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.113922

Table 8 Incidence of adverse events in the two groups

Adverse events	Grade	0	1	2	3	4	Incidence (%)	χ²	P value
WBC reduction	Treatment group	29	5	2	0	0	19^a
WBC reduction	Control group	19	10	2	1	1	42	4.29	0.038
NE reduction	Treatment group	31	3	1	1	0	14^a
NE reduction	Control group	21	5	4	1	2	36	4.68	0.03
HGB reduction	Treatment group	21	15	0	0	0	41^a
HGB reduction	Control group	11	19	3	0	0	67	3.90	0.048
PLT reduction	Treatment group	26	10	1	0	0	31^a
PLT reduction	Control group	15	15	3	0	0	55	4.06	0.04
ALT/AST elevation	Treatment group	29	7	0	0	0	19
ALT/AST elevation	Control group	25	8	0	0	0	24	0.23	0.63
Hypertension	Treatment group	11	15	7	3	0	69
Hypertension	Control group	7	12	9	5	0	79	0.78	0.38
Nausea/vomiting	Treatment group	31	4	1	0	0	13^a
Nausea/vomiting	Control group	21	8	3	1	0	36	4.68	0.030
Diarrhea	Treatment group	28	8	0	0	0	22^a
Diarrhea	Control group	17	12	2	2	0	48	5.23	0.022
Palmar-plantar erythrodysesthesia syndrome	Treatment group	25	10	1	0	0	30
Palmar-plantar erythrodysesthesia syndrome	Control group	19	12	2	0	0	42	1.05	0.306
Paresthesia	Treatment group	27	9	0	0	0	25
Paresthesia	Control group	23	9	1	0	0	30	0.243	0.62

^aP < 0.05 vs treatment group within the same group.

WBC: White blood cells; NE: Neutrophils; HGB: Hemoglobin; PLT: Platelets; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.

Citation: Qin HY, Li Z, Cong PW, Mi D, Li FZ, Hu X, Li GX. Clinical efficacy of Fuzheng Jiedu Xiaoyong granules in advanced colorectal cancer (spleen deficiency and stasis toxin syndrome). World J Gastrointest Oncol 2026; 18(2): 113922
URL: https://www.wjgnet.com/1948-5204/full/v18/i2/113922.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i2.113922

Qin HY, Li Z, Cong PW, Mi D, Li FZ, Hu X, Li GX. Clinical efficacy of Fuzheng Jiedu Xiaoyong granules in advanced colorectal cancer (spleen deficiency and stasis toxin syndrome). World J Gastrointest Oncol 2026; 18(2): 113922 [PMID: 41695913 DOI: 10.4251/wjgo.v18.i2.113922]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.